Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 7 , Pages 1147-1151 , July 2009

Analgesic Prescribing for Musculoskeletal Complaints in the Ambulatory Care Setting After the Introduction and Withdrawal of Cyclooxygenase-2 Inhibitors

Presented to the Association of Academic Physiatrists, February 2009, Colorado Springs, CO.

  • Richard D. Wilson, MD

      Affiliations

    • Corresponding Author InformationCorrespondence to Richard D. Wilson, MD, 2500 MetroHealth Dr, R-230, Cleveland, OH 44109

References 

  1. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA. 2000;284:1247–1255
  2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis (VIGOR Study Group). N Engl J Med. 2000;343:1520–1528
  3. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 200;286:954-9.
  4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102
  5. Phillips DM. JCAHO pain management standards are unveiled. JAMA. 2000;284:4–5
  6. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002;23:131–137
  7. Caudill-Slosberg MA, Schwarts LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in the US: 1980 vs. 2000. Pain. 2004;109:514–519
  8. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med. 2005;165:171–177
  9. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006;7:225–235
  10. Thiebaud P, Patel BV, Nichol MB. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health. 2006;9:361–368
  11. Williams D, Singh M, Hind C. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol. 2006;62:366–368
  12. Schüssel K, Schulz M. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. Pharmazie. 2006;61:878–886
  13. Barozzi N, Tett SE. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?. Pharmacoepidemiol Drug Saf. 2007;16:1184–1191
  14. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf. 2008;17:9–19
  15. National Center for Health Statistics. Ambulatory Health Care Data. http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htmAccessed September 26, 2008

 Supported by the Rehabilitation Medicine Scientist Training Program (grant no. K12-HD01097).

 No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

 Reprints are not available from the author.

PII: S0003-9993(09)00214-7

doi: 10.1016/j.apmr.2009.01.017

Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 7 , Pages 1147-1151 , July 2009

Article Tools

* Image Usage & Resolution